Efficacy of delgocitinib ointment for skin rashes in patients with atopic dermatitis.

Phase 4

• Conditions: Atopic dermatitis

• Registration Number: JPRN-jRCTs031230063
• Lead Sponsor: Masatoshi Abe

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-05-01
• Last Update Posted: 22 January 2024

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

(1) Patients aged 18 years and older with atopic dermatitis when obtaining consent.
(2) Patients using topical steroids or tacrolimus ointment* for face or neck rash for more than 3 months.
(3) Patients with local side effects such as skin atrophy, vasodilation, or rosacea-like dermatitis as a result of treatment with topical steroids or who are expected to use topical steroids for a long time and are concerned about the development of local side effects or patients with local side effects such as skin irritation, or rosacea-like dermatitis due to the use of tacrolimus ointment on the face or neck.
(4) Patients who have given written consent to participate in the study.
**: Any rank and formulation of topical steroids.
**: Any concentration of tacrolimus ointment.

Exclusion Criteria

(1) Patients using the strongest topical steroids on the face or neck.
(2) Patients using delgocitinib ointment on the face or neck.
(3) Patients using difamilast ointment.
(4) Patients with plaque or other erosions forming obvious foci at the observation site.
(5) Patients who are pregnant, may become pregnant, or plan to become pregnant during the study period.
(6) Patients who are breastfeeding
(7) Patients previously treated with delgocitinib ointment
(8) Patients receiving systemic therapy with internal medications (steroids, cyclosporine, JAK inhibitors) at the time consent was obtained or within the last 3 months.
(9) Patients receiving systemic therapy with biologics (e.g., dupilumab, nemolizumab) at the time consent was obtained or within the last 6 months
(10) Patients receiving phototherapy, such as ultraviolet light therapy, at the time consent was obtained or within the last 3 months.
(11) Patients who have participated in a clinical trial or similar within the last 6 months
(12) Patients deemed ineligible for the study by the investigator or others.

Study & Design

• Study Type: Interventional
• Study Design: Not specified